Published in final edited form as:

Appl Microbiol Biotechnol. 2013 July ; 97(14): 6427–6437. doi:10.1007/s00253-013-4839-4.

Biotransformation and recovery of the isoflavones genistein and daidzein from industrial antibiotic fermentations

J. Mark Weber^{1,§}, Andrew R. Reeves^{1,†}, Ramya Seshadri^{1,‡}, William H. Cernota¹, Melissa C. Gonzalez^{1,§}, Danielle L. Gray², and Roy K. Wesley¹

¹Fermalogic, Inc. 920 N. Franklin St., Chicago, Illinois 60610

²University of Illinois, School of Chemical Sciences, 505 S Matthews Ave., Urbana, Illinois 61801

Abstract

The objective of this study was to follow the metabolic fate of isoflavone glucosides from the soybean meal in a model industrial fermentation to determine if commercially useful isoflavones could be harvested as coproducts from the spent broth at the end of the fermentation. The isoflavone aglycones, genistein and daidzein, together make up 0.1 - 0.2% of the soybean meal by weight but serve no known function in the manufacturing process. After feeding genistein to washed cells of the erythromycin-producing organism, *Saccharopolyspora erythraea*, the first biotransformation product (Gbp1) was determined by x-ray crystallography to be genistein-7-O- α -rhamnoside (rhamnosylgenistein). Subsequent feeding of rhamnosylgenistein to growing cells of *S. erythraea* led to the production of a second biotransformation product, Gbp2. Chromatographic evidence suggested that Gbp2 accumulated in the spent broth of the erythromycin fermentation. When the spent broth was hydrolyzed with acid or industrial enzyme preparations the isoflavone biotransformation products were returned back to their parental forms, genistein and daidzein, which were then recovered as coproducts. Desirable features of this method are that it does not require modification of the erythromycin manufacturing process or genetic engineering of the producing organism to be put into practice. A preliminary investigation of five additional antibiotic fermentations of industrial importance were also found to have isoflavone coproduct potential.

Keywords

Isoflavones; genistein; daidzein; coproduct; soybean; fermentation; *Saccharopolyspora erythraea*; 7-O-rhamnosylgenistein

Introduction

Fermentation manufacturing is a controlled microbiological process that converts agricultural products such as soybean meal and corn starch, into pharmaceutical products such as antimicrobials, anti-cancer agents, anti-virals, immunosuppressants, herbicides, insecticides, and other natural products (Berdy, 2005). Although fermentation manufacturing of new products can often be improved through modifications of the strain and/or process (Queener and Lively, 1986), mature fermentations are more difficult to improve. Therefore in this study we investigated a new method for improving the economics

[#]Corresponding author: Mark Weber, 312-255-1090, mark.weber@fermalogic.com.

[†]Present address: Coskata, Inc., 4575 Weaver Pkwy., Suite 100, Warrenville, IL 60555.

[‡]Present address: Abbott Molecular, 1300 East Touhy Avenue, Des Plaines, IL 60018.

[§]Present address: Department of Cellular and Molecular Biology, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA

of fermentation manufacturing: through the recovery of value-added isoflavone co-products from the spent fermentation broth. Our principal model system was the erythromycin fermentation of *Saccharopolyspora erythraea* (Minas, 2007).

Spent broth from the erythromycin fermentation contains cell debris and the end-products of microbial metabolism, and is either disposed of or concentrated and sold as an animal feed supplement. More recently, enzymatic hydrolysis of the spent broth has been used as a way to further enhance its animal growth-promoting properties (Fidler et al., 2003a; Fidler et al., 2003b; Kidd et al., 2003). In this study we investigated the possibility of recovering a high value co-product from the spent broth: soy isoflavones. The project required that co-product recovery not have a negative impact on the production of the primary product, erythromycin A. By narrowing our search to the spent broth at the end of the fermentation, we ensured that we would not have to alter the manufacturing process for erythromycin in any way. Defatted soybean meal (that which remains of the soybean after the oil is removed and is referred to here simply as soybean meal) supplies protein and carbohydrates for growth of the antibiotic-producing organisms. However, soybean meal also contains isoflavones; and the ultimate fate of the isoflavone component in the soybean meal at the completion of the fermentation was not known prior to our studies. Isoflavones, also referred to as phytoestrogens for their estrogenic activity (Virk-Baker et al., 2010), have commercial value as nutraceuticals and as specialty chemicals used in biomedical research (Dijsselbloem et al., 2004). Since a typical commercial fermentor will consume over 3 metric tons of soybean meal per week and since isoflavones represent about 0.1 to 0.2% of the soybean meal by weight (Swanson et al., 2004; Murphy and Hendrich, 2002), about 3 - 6 kg of isoflavones are passed through a single fermentor per week. Multiplying this number by the number of fermentors per plant, and the number of soybean-based fermentation manufacturing plants around the world, the total scale of the potential recovery in terms of quantity can be estimated. Additionally, since the value of purified isoflavones can be as much as 10-times that of erythromycin, there is a significant economic incentive to pursue recovery of this co-product. The main question that we sought to answer in this study was as follows: what happens to the soy isoflavones during the erythromycin fermentation process and can biologically active isoflavones still be recovered at the end of the fermentation?

Many irreversible actinomycete biotransformations of isoflavones have been reported including hydroxylation, methylation, and chlorination (Chimura et al., 1975; Hosny and Rosazza, 1999; Komiya et al., 1989; Maatooq and Rosazza, 2005). It was thought possible that these or other biotransformations might be occurring in the *S. erythraea* fermentation. Some biotransformations may be desirable in cases where a change in the structure leads to enhanced or altered biological activity (Seo et al., 2011). Our goal, however, was to harvest a co-product that fit into an existing commercial market, hence our desire to recover isoflavones-- either the glucosides genistin and daidzin or the aglycones genistein, and daidzein.

We had shown previously that in soybean-based fermentations the isoflavone glucosides genistin and daidzin are first hydrolyzed to the aglycones with a β -glucosidase (Hessler et al., 1997; Reeves et al., 2008). We also had preliminary evidence that the aglycones were then further modified; but the nature of the later modification(s) and the enzyme(s) involved were unknown (Reeves et al., 2008).

We speculated that the isoflavone molecules could be irreversibly altered or completely metabolized during the fermentation. Therefore, in order to recover the active isoflavone glucosides or aglycones as co-products from the erythromycin fermentation spent broth, we initially assumed identification and inactivation through genetic engineering of genes at one or more steps in the isoflavone biotransformation pathway of *S. erythraea* (Hessler et al.,

1997) would be required. As we discovered from this study, however, these genetic manipulations are unnecessary because the majority of the genistein and daidzein added to the fermentation is not irreversibly modified. Thus, the isoflavone recovery process proposed here is one that would circumvent both the need for genetic engineering of the erythromycin-producing organism and the need for modification of any other aspect of the erythromycin production process.

Materials and Methods

Strains and growth media

The erythromycin-producing strain used for this study was the wild-type “white” *Saccharopolyspora erythraea* FL2267. FL2267 is a derivative of ATCC11635 (American Type Culture Collection; Manassas, VA) --the erythromycin-producing strain from which many industrial strains have been developed. FL2267 is a wild-type revertant obtained by eviction of a non-mutagenic integrated plasmid. The plasmid transformation and eviction process was performed to improve the suitability of *S. erythraea* FL2267 for transformation (United States Patent Application 20070122885). *S. erythraea* seed cultures were prepared in CFM1 broth (Carbohydrate-based Fermentation Medium; Reeves et al., 2006) and SCM broth (Reeves et al., 2004) was used for isoflavone feeding experiments where growing cells were used. Both CFM1 and SCM contain Bacto soytone (Difco Laboratories, Sparks, MD) in place of soybean meal, which contains only trace levels of isoflavones. Stirred-jar fermentations were performed in OFM1 broth (Oil-based Fermentation Medium; Reeves et al., 2006). The five additional *Streptomyces* strains used in this study are listed in Table 1.

Chemicals and biochemicals

Genistein, daidzein, genistin, daidzin and robinin were purchased from Indofine Chemicals (Hillsborough, NJ). Rhamnosylgenistein standards were prepared at Fermalogic, Inc by biotransformation of genistein from Indofine Chemicals. The enzyme α -glucosidase was type I from Baker's yeast (Sigma Chemicals, St. Louis, MO). β -glucosidase (from almonds) was purchased from Sigma. β -glucosidase (from fungi), β -glucanase, and pectinase were industrial grade enzymes from Bio-Cat (Troy VA). Validase $\times$ (hemicellulase and xylanase), Validase® BG (endo β -1,4 glucanase) and Crystalzyme® PML-MX (a mixture of cellulases, hemicellulases, pectinases, and arabinases) were industrial enzyme solutions purchased from Valley Research (South Bend, IN).

Chromatographic analyses

Analytical thin layer chromatography (TLC) was performed on Silica Gel 60 F₂₅₄ plates (Macherey-Nagel), 0.2 mm thickness. Plates were illuminated at 306 nm using a UVP transilluminator. The primary solvent system used was chloroform: methanol: water (80:20:2). Standards were prepared at 0.3 mg/ml in ethyl acetate. (Indofine, Hillsborough, NJ). HPLC analysis was performed on Hitachi instrument using Alltech Prevail C18 column 250 mm $\times$ 4.6 mm. Conditions for the 2-component mobile phase system were as follows: mobile phase A: 0.1% formic acid in H₂O; mobile phase B: 0.1% formic acid in acetonitrile. The gradient used was: 0 min. 75% A, 25% B; 10 min. 35% A, 65% B; 20 min. 75% A, 25% B. Preparative HPLC purification of compound Gbp1, GC/mass spectral analyses, and NMR analyses were performed under contract by Decode Genetics Analytical Chemistry Services (Lemont, IL).

Washed cell method for genistein and daidzein feeding experiments

4 ml of SCM medium was seeded with 5 μ l of *S. erythraea* spores (1×10^8 spores/ml, stored at -80°C) and incubated at 32°C for 48 hrs with shaking at 350 rpm. 2.5 ml of the four ml

seed culture was used to inoculate 25 ml of SCM medium in 250 ml flasks which were incubated at 32°C for 48 hr. The cells were harvested by centrifugation, washed in 25 ml of 50 mM potassium phosphate buffer (pH 7), resuspended in 20 ml of the same buffer, and incubated for 4 hrs after addition of 20 µg/ml of genistein or daidzein (Indofine Chemical Company). The reaction was stopped by centrifugation of the cells and extraction of the biotransformation products from the supernatant with 20 ml ethyl acetate. The reaction products were concentrated to a final volume 300 µl by evaporation.

Extraction and analysis of unhydrolyzed fermentation broth samples for thin layer chromatography

A 750 µl broth sample was transferred to an microfuge tube and extracted with 500 µl of ethylacetate:n-butanol (9:1). The solvent extract was evaporated to dryness and resuspended in 25 µl of acetonitrile. A TLC plate was spotted with 5 µl of each concentrated extract.

Acid hydrolysis of fermentation broth samples and analysis by thin layer chromatography

To 500 µl of fermentation broth in a 15 ml polypropylene test tube with screw cap closure, 250 µl of concentrated (12 N) hydrochloric acid were added. The tube was incubated at 80°C for 3.5 h, cooled, and two ml of water were added to the acidified solution. The aqueous mixture was extracted once with 1.5 ml of ethylacetate: n-butanol (9:1). The solvent layer was evaporated, and the remaining small residue was resuspended in 25 µl of ethyl acetate. Five µl of the resuspended product was spotted on thin layer silica gel plates which were developed and visualized.

Enzymatic hydrolysis of spent broth for unmasking isoflavone biotransformation products and the generation of genistein and daidzein

The pH of a 3 ml aliquot of thawed culture broth was adjusted to pH 3.0 with sulfuric acid and incubated at 80°C for 3.5 hrs. The sample was cooled to 45°C and two enzymes were added, Validase® BG (β-glucanase) and Crystallzyme® PML-MX (pectinase/cellulase) (30 µl each of a 1% stock solution) and incubated for 17 hours. The reaction was extracted with 3 ml of ethyl acetate: butanol (9:1), transferred to two microfuge tubes and dried *in vacuo*. The residue was resuspended in 50 µl of ethyl acetate. Five µl were spotted per lane.

Production and purification of compound Gbp1 (rhamnosylgenistein)

To produce rhamnosylgenistein by biotransformation of pure genistein, 5 microliters of a dense spore suspension (1×10^8 spores / ml) of *S. erythraea* was added to 40 ml of SCM broth in a 250 ml shake flask and the flask was incubated at 30°C and 400 rpm (1 inch orbital displacement) for 2 days. The entire 40 ml culture was transferred into a 2L shake flask containing 100 ml of SCM and 100 mg of genistein (fed directly to the medium from the vial), the cells were incubated at 30°C with shaking for 5 to 24 hrs. The broth was stored at 4°C until several batches were ready for purification.

To purify rhamnosylgenistein from the fermentation broth, the cells were first removed by centrifugation. The broth was then extracted twice with one-half volume of ethyl acetate and the solvent layers were combined and concentrated by evaporation under vacuum. The concentrated extracts were then applied to the top of a 12 g silica-gel flash chromatography column and processed on an Isco, Inc. Combi-Flash Companion Flash chromatography apparatus using a linear gradient elution method programmed to run from a starting condition of 25% hexane and 75% ethyl acetate to a finishing condition of 100% ethyl acetate over a 15 minute run. The individual fractions containing pure rhamnosylgenistein were identified by thin layer chromatography as spot Gbp1. They were combined and dried completely *in vacuo*. The dried powder was then suspended in 80% ethanol, heated to 90°C

and dissolved completely, followed by cooling at 4°C. Crystals appeared over the next several days and were washed with cold ethanol and dried *in vacuo*.

Diagnostic enzyme treatment of purified genistein-7-O- α -rhamnoside

Five μ l of a 6 mg/ml solution of genistein-7-O- α -rhamnoside in ethanol was added to 100 μ l of distilled water. Two μ l of a 20 mg/ml stock solution of enzyme was added to the compound and the mixture was incubated for 1 hour at 45°C. The reaction was dried in vacuo and resuspended in 20 μ l of ethyl acetate. Five μ l were spotted per lane. The source of the enzymes used is given above.

X-Ray crystallography

For X-ray structure analyses the crystals were mounted onto a 0.3 mm cryo-loop, and data collection was performed at 193 K using graphite monochromated CuK α radiation (λ = 1.54178 Å) with a BRUKER-AXS Kappa APEX II diffractometer. Cell refinements and data reductions were carried out with SAINT in APEX2 (*Bruker APEX2 Version 2009.5-1 and SAINT version 7.34a Data Collection and Processing Software*; Bruker Analytical X-Ray Instruments, Inc.: Madison, WI). Numerical face-indexed absorption corrections were applied using SADABS (Sheldrick, 2008a). Structure determinations were carried out by direct methods with XS and least-squares refinements were carried out with XL of the SHELX (Sheldrick, 2008b) package. All diagrams were drawn with 35% probability thermal ellipsoids. Crystallographic details are given in Table 2. Additional data is in Supplementary Tables S1-S5.

Crystallographic data (excluding structure factors) for the structures of compound **Gbp1** reported in this paper have been deposited with the Cambridge Crystallographic Data Center [CCDC 899254]. Copies of the data can be obtained free of charge on application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, U.K. [fax: (international) +44-1223/336-033; deposit@ccdc.cam.ac.uk].

Stirred-Jar fermentation method

The seed culture was prepared in 25 ml CFM1 broth in shake flasks. Seven shake flasks were prepared per fermentor. The seed cultures were inoculated with 15 μ l of 2-week old spores that had been stored in glycerol and frozen at –80°C. The flasks were incubated at 32°C while shaking at 280 rpm with a 1-inch circular displacement and grown for 40 hr. The fermentation was performed in New Brunswick BioFlo 110 modular benchtop fermentors, using BioCommand Plus software Revision A 2002. The fermentors were filled with 2L of sterile OFM1 broth and inoculated with 100 ml of seed culture. One hundred mls of a 10% solution of sterile glucose were also added to the culture medium at this point. Crude soy oil was added to the fermentation starting at 12 hr post inoculation at a rate of 3.3 ml/minute. Samples of the fermentation broth were taken at regularly scheduled intervals throughout the course of the 5-day fermentation. The samples were flash frozen in a –80°C ethanol bath, then stored at –20° C. Fermentations were performed at 32.5°C, minimum agitation at 600 rpm, cascaded to maintain dissolved oxygen at above 20% for approximately 5-6 days. At the completion of the fermentation the cultures were streaked on E20A agar plates to confirm that the fermentations were not contaminated.

Results

Evidence of isoflavone biotransformation from the erythromycin fermentation

A laboratory-scale fermentation, modeled after the commercial *Saccharopolyspora erythraea* erythromycin fermentation, was performed in two-liter stirred-jar fermentors. Broth samples

were taken from the fermentors, extracted with ethylacetate:n-butanol (9:1), concentrated, and analyzed by thin layer chromatography (TLC). The sample time points were: (i) 0 hr - before the start of the fermentation, (ii) 12 hrs into the fermentation, and (iii) 120 hr - the spent broth at the completion of the fermentation on day 5 (Fig. 1A).

At 0 hr the two most prominent bands were genistin and daidzin (labeled “g” and “d” respectively). This was not unexpected because these glucosides are known to be the predominant isoflavones in soybean meal (Fig. 1A, 0 hrs). At 12 hr the isoflavone aglycones, genistein and daidzein were most prominent (“G” and “D”). This was also not unexpected, because genistein and daidzein are created from genistin and daidzin by enzymatic hydrolysis during the early hours of the *S. erythraea* fermentation (Fig. 1A 12 hrs; Hessler et al., 1997; Reeves et al., 2008). However in the spent broth (120 hr), none of the four isoflavone structures from the early fermentation were visible. Instead a new collection of unknown UV-absorbing compounds appeared (Fig. 1A, 120 hrs). In order to better determine which of the compounds in the 120 hr sample were related to isoflavones, feeding experiments using single purified isoflavones were performed in non-soybean meal containing liquid media.

Evidence of genistein biotransformation from feeding experiments

Feeding experiments were performed to better understand the biotransformation process in more controlled conditions. The results of the genistein and daidzein feeding experiments (Fig. 1B) showed that genistein was rapidly converted into a slower moving product, genistein biotransformation product no. 1 (Gbp1), and similarly, daidzein was converted to Dbp1. Dbp1 moved slightly slower than Gbp1, and therefore appears below it on TLC (Fig. 1B), similar to the way daidzein moves slightly slower than genistein, and daidzin moves similarly slower than genistin on TLC (Fig. 1A). Also, Dbp1 matches band bp3 from the spent fermentation broth (120 hr, Fig. 1A).

Continuing with the second-stage of the feeding experiment, compound Gbp1 was produced and purified in larger amounts, and then fed to *S. erythraea* cells. A new slower moving spot, Gbp2, was identified. In this experiment Gbp1 was completely biotransformed into Gbp2 after 24 hrs (Fig. 1C). In reference to the previous experiment, compound Gbp2 matched up in mobility on TLC (Fig. 1C, 24 hrs) with band bp1 from the unhydrolyzed spent fermentation broth (Fig. 1A 120 hrs). Both bands Gbp2 and bp1 traveled half-way between the robinin (R) and daidzin (d) reference standards (Fig. 1A, 120 hrs).

Analysis of fermentation broth and isoflavone biotransformation products by acid and enzyme hydrolysis

In order to help determine whether bp1 and bp2 from the 120 hr sample were related to the isoflavones, they were co-purified by flash chromatography and subjected to acid hydrolysis (Fig 2B). At the high acid concentrations (1-, 2-, and 4N) the only visible products of the reaction were genistein and daidzein, which confirmed the connection of these biotransformation products to the isoflavone parent compounds. Lower acid concentrations (0.05- and 0.1 N) revealed the first-stage conversion products, Gbp1 and Dbp1, which also confirmed a connection with the first-stage biotransformation products.

In a related experiment when fermentation samples were analyzed, all three time points gave similar looking hydrolytic profiles, that is, genistein and daidzein were the main products regardless of what time the samples were taken (Fig. 2A). The identity and concentrations of genistein and daidzein in these hydrolyzed samples was confirmed by high pressure liquid chromatography (HPLC). The levels of genistein and daidzein at the end of the fermentation were found to be 100% (+/- 10%) and 67% (+/-3%) of their starting levels. Structures of

the glucosylated isoflavones genistin and daidzin, and structures of their hydrolytic products genistein and daidzein, are shown (Fig. 2D).

In related work, purified compound Gbp1 was subjected to hydrolysis by commercial glycosidic enzyme preparations revealing its susceptibility to these enzymes (Fig. 2C). Three enzyme preparations showed reactivity with Gbp1, and each of the active enzyme mixtures converted Gbp1 back to genistein (G). These reactions were not run to completion and therefore show both compounds. The three active enzyme preparations were a mixture of fungal α - + β -glucosidase from Bio-cat (lane 2), a pectinase from Bio-cat (lane 3), and crystalzyme from Valley Research (lane 4). These industrial preparations contained crude mixtures of enzymes that could hydrolyze a wide variety of glycosidic bonds.

Compound Gbp1 was determined to be genistein-7-O- α -rhamnoside (rhamnosylgenistein)

In order to determine the structure of Gbp1, larger amounts of the compound were produced, purified by flash chromatography, and analyzed by HPLC, high resolution mass spectrometry, COSY NMR, and x-ray crystallography. Compound Gbp1 appeared as a single peak and eluted just prior to daidzein on HPLC (Fig. 3A). Using mass spectrometry, the molecular ion of compound Gbp1 in ESI positive mode was found to be 417. Coupling with the ESI negative results of molecular ion at 415, the molecular weight of compound Gbp1 was determined to be 416 (Fig. 3B). Tandem mass spectrometry fragmentation analysis was carried out to compare genistein (m/z 271), genistin (m/z 433), and compound Gbp1. The fragmentation pattern of m/z 271 from compound Gbp1 matched the pattern of m/z 271 from genistin (Fig. 3B, inset). Based on the above results, the full structure of genistein must be present within compound Gbp1 as it is within genistin.

Finally compound Gbp1 was crystallized from 80% ethanol and subjected to x-ray crystallographic analysis. Its structure was determined to be genistein-7-O- α -rhamnoside, (IUPAC name: 5-hydroxy-3-(4-hydroxyphenyl)-7-(((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-trihydroxy-6-methyltetrahydro-2*H*-pyran-2-yl)oxy)-4*H*-chromen-4-one) (Fig. 4A, Table 2, Supplemental Information Tables S1-S5). The rhamnosyl group is shown as the natural L isomer (an assumption at this point) and is attached by an α -linkage to the core isoflavone structure at C-7, whereas in genistin, a glucosyl group is linked at the same C-7 location by a β -linkage. Structures of the known intermediates in the genistin bio-transformation pathway are shown (Fig. 4B).

Acid hydrolysis of five additional industrial actinomycete fermentations reveals hidden isoflavone content

Five additional Actinomycete species of commercial importance were compared to *S. erythraea* for their isoflavone coproduct potential. The results (Fig. 5; Table 1) showed all five fermentations to have at least some isoflavone co-product potential, particularly for genistein recovery. Daidzein was absent in the case of *S. glaucescens* (Fig. 5B, lane 4) and weak for *S. avermitilis* (Fig. 5B, lane 2). The results also show that it is impossible to predict from the analysis of the unhydrolyzed spent broth whether a strain will have good coproduct potential or not. Comparing the *S. glaucescens* and *S. rimosus* profiles before hydrolysis, both have nearly blank profiles with no bands (Fig. 5A, lanes 4 and 6), indicating complete biotransformation or destruction of the isoflavones. After hydrolysis, *S. rimosus* had strong bands for genistein and daidzein (Fig. 5B, lane 6), whereas *S. glaucescens* had a weak band for genistein and a very weak band for daidzein (Fig. 5B, lane 4). The results suggest that *S. glaucescens* has a biotransformation process that involves irreversible biotransformation or destruction of the isoflavones, whereas *S. rimosus*, like *S. erythraea*, has a reversible masking pathway for the majority of the isoflavone material in the fermentation.

Other ways that industrial actinomycetes can vary is in the type of biotransformation products they produce. *S. cinnamomensis* (Fig. 5A, **lane 3**) for example, showed four new UV absorbing bands, different from those seen previously with *S. erythraea*. All of these presumed biotransformation products, however, could be converted back to genistein and daidzein by acid hydrolysis (Fig. 5B, **lane 3**).

These results show that *S. erythraea* is not unique in its ability to biotransform isoflavones, and that commercially useful isoflavones should also be recoverable from other industrial fermentations following acid or enzyme hydrolysis of their spent broth.

Discussion

As a result of this study we showed that it is possible to efficiently recover isoflavone coproducts from laboratory scale industrial antibiotic fermentations. We initially assumed that this would require genetic engineering to block the isoflavone biotransformation process, but this was discovered not to be necessary. Although it is true that isoflavones *are* highly altered by *S. erythraea* in a multistep biotransformation process, the modifications can be allowed to proceed because they can be reversed at the end of the fermentation. The spent broth was chosen as the source of coproducts since harvesting at the end of the fermentation, rather than at an earlier time point, insures that the coproduct recovery process will not possibly interfere with the production of the primary product, erythromycin A. When dealing with an industrial process of this magnitude it is highly desirable that interference with the existing process be held to a minimum; and two advantages of this system are that neither the existing erythromycin manufacturing process, nor the producing organism need be altered.

Our results showed that the first stage of genistein biotransformation is characterized by the rhamnosylation of the C-7 hydroxyl group. Evidence for a second, and possibly final, stage of genistein's biotransformation process was also obtained, and the chemical and biological characterization of later biotransformation product(s) is currently under investigation and will be reported elsewhere.

That a rhamnosylase was involved in the biotransformation pathway led to attempts to genetically block this step (Fig. 5B); however, this approach was abandoned, after extensive efforts proved unsuccessful (I. A. Brikun, A. R. Reeves and J. M. Weber, unpublished data). This approach, had it been technically possible, would have required that a new genetically engineered modification be put into each industrial production strain, and this we predict, would be less appealing to industry than the approach we propose here.

Glycosylation is a mechanism used to confer resistance to antibiotics used by some actinomycetes (Quirós et al., 1998), and glycosylation is not an uncommon microbial biotransformation reaction. However, some insight into why this biotransformation occurs to isoflavones can be found from a previous report which describes the rhamnosylation of another phenolic compound, flaviolin, by *S. erythraea* (Cortes et al., 2002). Flaviolin is a natural product involved in formation of the red pigment that is bio-synthesized by *S. erythraea* and is nearly identical to the A and C rings of the isoflavone core structure (Fig. 4C). Furthermore, the rhamnosyl group is transferred to the equivalent oxygen atom on each structure. Therefore genistein is highly likely to be acted upon by the same rhamnosylase that biotransforms flaviolin. The production of flaviolin and rhamnosylflaviolin by *S. erythraea* could explain the appearance of the additional spots seen in the spent broth sample extract, particularly bp4 and bp5 (120 hr, Fig. 1A).

In reference to the commercial applications of this study, it is theoretically likely that our results will extrapolate to large-scale commercial fermentors using high producing strains. This is because, although commercial strains will contain hundreds of different mutations, it is likely that the vast majority of them would confer a loss of biochemical or genetic function rather than a gain of function. Therefore the commercial strains should show equal or less biotransforming ability than the wild type strain, rather than more. That said, each different manufacturing process could have a variable influence on the biotransformation pathway, and therefore each strain and process will have to be tested separately to answer this question. A basic flow diagram for an idealized erythromycin fermentation process including isoflavone biotransformation and coproduct recovery is shown (Fig. 6).

In conclusion, chemically altered or “masked” forms of genistein and daidzein were found in the spent broth of the erythromycin fermentation (120 hr, stars, Fig. 6). Once erythromycin is removed (light grey circles, step 3, Fig. 6), the spent broth can then be hydrolyzed with acid or enzyme treatments to convert isoflavones (stars) to their parental forms, genistein and daidzein (step 4, dark grey circles, Fig. 6), which are then recovered from the treated broth by solvent extraction (step 5, Fig. 6). Hydrolysis releases or “unmasks” isoflavone biotransformation products into their commercially useful parental form. In addition, a preliminary survey revealed that other industrial antibiotic fermentations also have this potential to serve as sources of isoflavone coproducts.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge the Small Business Innovation Research program and the National Institutes of Health for grants R43 CA93165 and R44 CA93165 from the National Center for Complementary and Alternative Medicine. We acknowledge Igor Brikun, Andrey Fedashtchin, Noelle Kwan, Ben Leach, Cheryl Iverson, and John Aikens for helpful discussions.

References

- Bérday J. Bioactive Microbial Metabolites, A Personal View. *J Antibiot.* 2005; 58:1–26. [PubMed: 15813176]
- Chimura H, Sawa T, Kumada Y, Naganawa H, Matsuzaki M, Takita T, Hamada M, Takeuchi T, Umezawa H. New isoflavones, inhibiting catechol-O-methyltransferase, produced by *Streptomyces*. *J Antibiot.* 1975; 28:619–626. [PubMed: 1184476]
- Cortes J, Velasco J, Foster G, Blackaby AP, Rudd BA, Wilkinson B. Identification and cloning of a type III polyketide synthase required for diffusible pigment biosynthesis in *Saccharopolyspora erythraea*. *Molecular Microbiology.* 2002; 44:1213–1224. [PubMed: 12028378]
- Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. *Biochem Pharmacol.* 2004; 68:1171–1185. [PubMed: 15313415]
- Fidler DJ, George B, Quarles CL, Kidd MT. Broiler Performance and Carcass Traits as Affected by Dietary Liquid *Saccharopolyspora Solubles* Concentrate. *J Appl Poult Res.* 2003a; 12:153–159.
- Fidler, DJ.; Lampel, JS.; Weyant, DB. Concentrated spent fermentation beer or *Saccharopolyspora erythraea* activated by an enzyme mixture as a nutritional feed supplement. U.S. patent 6,616,953. Sep. 2003b
- Hessler PE, Larsen PE, Constantinou AI, Schram KH, Weber JM. Isolation of isoflavones from soy-based fermentations of the erythromycin-producing bacterium *Saccharopolyspora erythraea*. *Appl Microbiol Biotechnol.* 1997; 47:398–404. [PubMed: 9163954]

- Hosny M, Rosazza J. Microbial hydroxylation and methylation of genistein by Streptomyces. J Nat Prod. 1999; 62:1609–1612.
- Kidd MT, Fidler DJ, Koch KB, George B, Quarles CL. Dietary addition of liquid *Saccharopolyspora solubles* concentrate positively affects pellet mill throughput and broiler performance. J Appl Poult Res. 2003; 12:145–152.
- Komiyama K, Funayama S, Anraku Y, Mita A, Takahashi Y, Omura S, Shimasaki H. Isolation of isoflavonoids possessing antioxidant activity from the fermentation broth of Streptomyces. J Antibiot. 1989; 42:1344–1349. [PubMed: 2793588]
- Maatooq GT, Rosazza JP. Metabolism of daidzein by *Nocardia species* NRRL 5646 and *Mortierella isabellina* ATCC 38063. Phytochemistry. 2005; 66:1007–1011. [PubMed: 15896369]
- Minas, W. Production of erythromycin with *Saccharopolyspora erythraea*. In: Barredo, JL., editor. Methods in Biotechnology. Vol. 18. Microbial Processes and Products Humana Press; Totowa, NJ: 2005. p. 65-89.
- Murphy PA, Hendrich S. Phytoestrogens in foods. Advances in Food and Nutrition Research. 2002; 44:195–246. [PubMed: 11885137]
- Queener, SW.; Lively, DH. Manual of Industrial Microbiology and Biotechnology. Demain, AL.; Soloman, NA., editors. American Society for Microbiology; Washington DC: 1986. p. 155-169.
- Quirós LM, Aguirrezabalaga I, Olano C, Méndez C, Salas JA. Two glycosyltransferases and a glycosidase are involved in oleandomycin modification during its biosynthesis by *Streptomyces antibioticus*. Mol Microbiol. 1998; 28:1177–1185. [PubMed: 9680207]
- Reeves AR, WH Cernota WH, Brikun IA, Wesley RK, Weber JM. Engineering precursor flow for increased erythromycin production in *Aeromicrobium erythreum*. Metab Eng. 2004; 6:300–312. [PubMed: 15491860]
- Reeves AR, Brikun IA, Cernota WH, Leach BI, Gonzalez MC, Weber JM. Effects of methylmalonyl-CoA mutase gene knockouts on erythromycin production in carbohydrate-based and oil-based fermentations of *Saccharopolyspora erythraea*. J Ind Microbiol Biotechnol. 2006; 33:600–609. [PubMed: 16491356]
- Reeves, AR.; Weber, JM.; Brikun, IA. Methods of increasing production of secondary metabolites by manipulating metabolic pathways that include methylmalonyl-CoA. United States Patent Application 20070122885. 2007.
- Reeves AR, Seshadri R, Brikun IA, Cernota WH, Gonzalez MC, Weber JM. Knockout of the erythromycin biosynthetic cluster gene, *eryBI*, blocks isoflavone glucoside bioconversion during erythromycin fermentations in *Aeromicrobium erythreum* but not in *Saccharopolyspora erythraea*. Appl Environ Microbiol. 2008; 74:7383–7390. [PubMed: 18836015]
- Seo J, Kang S, Kim M, Han J, Hur HG. Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011; 91:219–228. [PubMed: 21626021]
- Sheldrick, GM. SADABS; Department of Structural Chemistry. University of Göttingen; Göttingen, Germany: 2008a.
- Sheldrick GM. Acta Crystallogr, Sect A: Found Crystallogr. 2008b; 64:112–122.
- Swanson M, Stoll M, Schapaugh W, Takemoto L. Isoflavone Content of Kansas Soybeans. American Journal of Undergraduate Research. 2004; 2:27–32.
- Virk-Baker MK, Nagy TR, Barnes S. Role of phytoestrogens in cancer therapy. Planta Med. 2010; 76:1132–42. Epub 2010 Jul 1. [PubMed: 20597043]
- Weber.

Figure 1. The isoflavone biotransformation process analyzed by thin layer chromatography
A. Extracts from three different time points (0 hr, 12 hr, and 120 hr) during the fermentation.
B. Feeding experiment where genistein and daidzein were fed to washed cells of *S. erythraea*. Lane 1, genistein reference standard; lane 2, extract from the genistein reaction after 4 hr incubation at 32°C; lane 3, daidzein reference standard; lane 4, extract from the daidzein reaction after 4 hr incubation at 32°C. Solvent system, hexane: ethylacetate: methanol (20:20:8). Arrows indicate the direction of biotransformation from the isoflavone aglycones to their first biotransformation products. **C.** Biotransformation of genistein biotransformation product 1 (Gbp1). Gbp1 was reacted with *S. erythraea* growing in SCM broth for the indicated period of time. Lane S, reference standards; lane M, medium sample prior to the start of incubation. Abbreviations: G, genistein; D, daidzein; Gbp1, genistein biotransformation product 1; Gbp2, genistein biotransformation product 2; Dbp1, daidzein biotransformation product 1; g, genistin; d, daidzin; R, robinin (an unrelated isoflavone used as a standard for its three sugar groups). The plates, containing a fluorescence indicator, were developed in chloroform: methanol: water (80:20:2) and photographed under ultra violet light illumination. A Dbp1 reference standard is not included in lane S, however Dbp1 can be seen in lanes 0h and 12h, paired up with Gbp1 which migrates just above it.

Figure 2. Acid and enzyme hydrolysis of fermentation samples and purified compounds from the fermentation

A. Extracts from the three time points after strong acid hydrolysis. **B.** Hydrolysis of isoflavone biotransformation products bp1 and bp2 that were purified from the spent broth of an OFM1 stirred-jar fermentation. Acid concentrations ranged from 0N to 4N HCl. Acid treatment was at 80°C for 0.5 hrs. Abbreviations: S, reference standards; G, genistein; D, daidzein; Gbp1, genistein biotransformation product 1; Dbp1, daidzein biotransformation product 1; g, genistin; d, daidzin; R, robinin. A reference standard for Dbp1 was not available, but its migration position can be best observed in lane 0.1 N just beneath Gbp1. The plates were developed in chloroform:methanol:water (80:20:2). **C.** Extracts from reactions of industrial enzymes with purified compound Gbp1. Lane 1, untreated Gbp1; lane 2, a mixture of fungal α -glucosidases and β -glucosidases; lane 3, Bio-cat pectinase; lane 4, Crystalzyme® PML-MX (a mixture of cellulases, hemicellulases, pectinases, and arabinases). **D.** Isoflavone acid or enzyme hydrolysis showing chemical structures. Abbreviations: S, reference standards; G, genistein; D, daidzein; Gbp1, genistein biotransformation product 1; g, genistin; d, daidzin; R, robinin. The plate was developed in chloroform:methanol:water (80:20:2).

Figure 3.

A. HPLC analysis of compound Gbp1 with three isoflavone reference standards, genistin, daidzein, and genistein. **B.** Mass spectral analysis of compound Gbp1 (large chart).

Comparative mass spectral analysis of genistin (top) with compound Gbp1 (bottom) in the fragment m/z 271 (inset charts).

Figure 4.

A. Compound Gbp1, genistein-7-O- α -rhamnoside, determined from x-ray crystallographic analysis. (See supplemental information). **B.** *S. erythraea* biotransformation pathway for genistin. The C-5 hydroxyl (gray shading) is replaced with a hydrogen in the daidzein molecule. **C.** *S. erythraea* biotransformation of flaviolin (23).

Figure 5.

Analysis of extracts from a collection of antibiotic fermentations before (left panel) and after (right panel) acid hydrolysis of the spent broth. S, isoflavone reference standards; C, uninoculated OFM1 media containing soyflour; 1, *Saccharopolyspora erythraea* ATCC 11635 (erythromycin); 2, *Streptomyces avermitilis* ATCC 31272 (avermectin); 3, *Streptomyces cinnamonensis* ATCC 15413 (monensin); 4, *Streptomyces glaucescens* NRRL B2899 (tetracenomycin); 5, *Streptomyces hygroscopicus* ATCC 25253 (rapamycin); and 6, *Streptomyces rimosus* ATCC 23955 (tetracycline). Abbreviations: S, reference standards; C, OFM1 medium control; G, genistein; D, daidzein; Gbp1, genistein biotransformation product 1; Dbp1, daidzein biotransformation product 1; bp1, biotransformation product 1; g, genistin; d, daidzin; R, robinin. The plates were developed in chloroform:methanol:water (80:20:2).

Figure 6.

Basic outline of a proposed commercial process to produce isoflavone coproducts from a soybean-based antibiotic fermentation. Fermentors are shown at the three time points from which samples were taken for analysis (Fig. 1). Following the completion of the fermentation the spent broth is shown being transferred to an extraction chamber (step 3) at which point the erythromycin (light gray circles) is removed. The spent broth is then hydrolyzed (step 4) which converts the isoflavone biotransformation products (stars) into genistein and daidzein (dark gray circles) which are then extracted (step 5). The extracted isoflavones can then be further purified and the remaining spent broth can then be handled as it was before the isoflavones were removed.

Table 1

Summary of genistein and daidzein coproduct potential of Industrial antibiotic fermentations shown in Fig. 5.

Species	Primary Fermentation product	de-glycosylation ^a	conversion of aglycones ^b	genistein coproduct potential ^c	daidzein coproduct potential ^c
S. Reference standards					
C. Uninoculated media		no	no	Yes	Yes
1. <i>Saccharopolyspora erythraea</i> ATCC 11635	erythromycin (antibiotic)	yes	yes	Yes	Yes
2. <i>Streptomyces avermitilis</i> ATCC 31272	avermectin (antiparasitic)	yes	yes	Yes	low
3. <i>Streptomyces cinnamonensis</i> ATCC 15413	monensin (animal growth promotant)	yes	yes	Yes	Yes
4. <i>Streptomyces glaucescens</i> NRRL B2899	tetracenomycin (anticancer agent)	yes	yes	Yes	very low
5. <i>Streptomyces hygroscopicus</i> ATCC 25253	rapamycin (immunosuppressant)	yes	yes	Yes	Yes
6. <i>Streptomyces rimosus</i> ATCC 23955	tetracycline (antibiotic)	yes	yes	Yes	Yes

^a strain has the ability to deglycosylate isoflavone glucosides (genistin and daidzin) to produce isoflavone aglycones (genistein and daidzein).

^b strain has the ability to biotransform the isoflavones genistein and daidzein to other biotransformation products.

^c potential after acid or enzyme hydrolysis.

Table 2Crystal Data and Structure Refinements for Gbp1 (genistein-7-O- α -rhamnoside).

Temperature	193(2) K
Wavelength	1.54178 Å
Formula weight	434.39
Crystal system	Monoclinic
Space group	P 2 ₁
Unit cell dimensions	$a = 8.5633(6)$ Å $\alpha = 90^\circ$ $b = 6.8692(5)$ Å $\beta = 95.762(5)^\circ$ $c = 17.1363(12)$ Å $\gamma = 90^\circ$
Volume	1002.92(12) Å ³
Z	2
Density (calculated)	1.438 Mg/m ³
Absorption coefficient	0.986 mm ⁻¹
$R(F)^a$	0.0348
$R_w(F^2)^b$	0.0829

$$^a R(F) = \Sigma |F_o| - |F_c| / \Sigma |F_o| \text{ for } F_o^2 > 2\sigma(F_o^2).$$

$$^b R_w(F^2) = \{ \Sigma [w(F_o^2 - F_c^2)^2] / \Sigma w F_o^4 \}^{1/2} \text{ for all data. } w^{-1} = \sigma^2(F_o^2) + (0.048P)^2 + 0.0038P \text{ where } P = [(F_o^2) - 2(F_c^2)]/3 \text{ for } F_o^2 > 0; w^{-1} = \sigma^2(F_o^2) \text{ for } F_o^2 < 0.$$